Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (16)

2024

  1. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023)

    Revista Espanola de Cardiologia, Vol. 77, Núm. 11, pp. 936-946

2023

  1. Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; the HOPE-Covid-19 Registry

    Anti-Infective Agents, Vol. 21, Núm. 2, pp. 66-78

2022

  1. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: The SUGAR trial

    European Heart Journal, Vol. 43, Núm. 13, pp. 1320-1330

2021

  1. Thin- versus thick-strut polymer-free biolimus-eluting stents: The BioFreedom QCA randomised trial

    EuroIntervention, Vol. 17, Núm. 3, pp. 233-239

2018

  1. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents

    JACC: Cardiovascular Interventions, Vol. 11, Núm. 10, pp. 981-991

  2. Clinical outcomes and prognosis markers of patients with liver disease undergoing transcatheter aortic valve replacement a propensity score⇓matched analysis

    Circulation: Cardiovascular Interventions, Vol. 11, Núm. 3

2015

  1. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis of Drug-Eluting Stents the RIBS IV Randomized Clinical Trial

    Journal of the American College of Cardiology, Vol. 66, Núm. 1, pp. 23-33

  2. Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: A meta-analysis

    Heart, Vol. 101, Núm. 17, pp. 1395-1405

  3. Cost-effectiveness of a European ST-segment elevation myocardial infarction network: Results from the Catalan Codi Infart network

    BMJ Open, Vol. 5, Núm. 12

  4. Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis)

    EuroIntervention, Vol. 11, Núm. 3, pp. 336-342

2014

  1. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: The RIBS v clinical trial (restenosis intra-stent of bare metal stents: Paclitaxel-eluting balloon vs. everolimus-eluting stent)

    Journal of the American College of Cardiology, Vol. 63, Núm. 14, pp. 1378-1386

2006

  1. A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis. Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial

    Journal of the American College of Cardiology, Vol. 47, Núm. 11, pp. 2152-2160

  2. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis: Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial

    American Heart Journal, Vol. 151, Núm. 3, pp. 681.e1-681.e9

2003

  1. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis

    Journal of the American College of Cardiology, Vol. 42, Núm. 5, pp. 796-805

2002

  1. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement

    Clinical Therapeutics, Vol. 24, Núm. 8, pp. 1332-1344

2000

  1. Eine konsequente lipidsenkende therapie zeigt eine ähnliche effektivität wie die koronarangioplastie bei patienten mit interventionsbedürftigen koronarstenosen

    Herz Kreislauf, Vol. 32, Núm. 3, pp. 84